Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio A Emini

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strainsFengqi Zhang, Kevin T Chapman, William A Schleif, et al.
Pediatrics|August 25, 2010
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlersSylvia H Yeh, Alejandra Gurtman, David C Hurley, et al.
Virology|January 16, 2007
Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infectionZhi-Qiang Zhang, Danilo R Casimiro, William A Schleif, et al.
Journal of Virology|September 5, 2002
Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccinesMichael J Caulfield, Su Wang, Jeffrey G Smith, et al.
Vaccine|May 8, 2016
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and olderRobert W Frenck, Anne Fiquet, Alejandra Gurtman, et al.
AIDS (London, England)|September 10, 2003
Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failuresRafael E Campo, Jose N Moreno, German Suarez, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
Vaccine|February 25, 2015
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adultsMichael Nissen, Helen Marshall, Peter Richmond, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Journal of Virology|September 29, 2004
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectorsDanilo R Casimiro, Andrew J Bett, Tong-ming Fu, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strainsFengqi Zhang, Kevin T Chapman, William A Schleif, et al.
Pediatrics|August 25, 2010
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlersSylvia H Yeh, Alejandra Gurtman, David C Hurley, et al.
Virology|January 16, 2007
Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infectionZhi-Qiang Zhang, Danilo R Casimiro, William A Schleif, et al.
Journal of Virology|September 5, 2002
Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccinesMichael J Caulfield, Su Wang, Jeffrey G Smith, et al.
Vaccine|May 8, 2016
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and olderRobert W Frenck, Anne Fiquet, Alejandra Gurtman, et al.
AIDS (London, England)|September 10, 2003
Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failuresRafael E Campo, Jose N Moreno, German Suarez, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
Vaccine|February 25, 2015
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adultsMichael Nissen, Helen Marshall, Peter Richmond, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Journal of Virology|September 29, 2004
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectorsDanilo R Casimiro, Andrew J Bett, Tong-ming Fu, et al.
Pageof 9